News

Why cancer research should focus on patients

Dr Azra Raza, Professor of Medicine at Columbia University in New York, international authority on leukaemia, and Science Adviser to Safer Medicines Trust, has written a remarkable and highly recommended new book published in October 2019: The First Cell: And the human costs of pursuing cancer to the last

In amongst highly moving stories of her patients, including her own husband, Dr Raza explains why the global cancer research effort should make two major changes of direction:

1) to focus on prevention and early detection, to find the first malignant cell instead of attacking late-stage disease; and

2) to focus research exclusively on humans and their tissues, rather than on mice, rats and other futile animal models.

To that end, she has founded the First Cell Center, to study her tissue repository of more than 60,000 samples collected from her patients over the past 35 years.

Many articles and interviews are available from https://azraraza.com. This video: Early Footprint and this news article: Here’s why we’re losing the war on cancer, according to this doctor are a great place to start, along with this powerful and moving 13-minute TEDx Talk from 2014.

Share
Follow Us

Latest Blog Posts

More harm than good? We need to talk about this!

As a patient safety charity whose raison d’etre is to reduce adverse drug reactions, Safer Medicines Trust is deeply concerned by the incidence of adverse reactions following covid-19 vaccinations. This is not what anyone wanted, following their remarkable development with such unprecedented speed – but it is certainly something that health systems should have been on high […]

‘Five For Friday’; Starting 2022 with five examples of human-relevant science using new approach methodologies (NAMs)

By Rebecca Ram Many research methods which focus on human-relevant biology (NAMs) are in use worldwide. However, a co-ordinated analysis of all existing methods that could be harmonised for global regulatory approval, as well as diversion of funding to the development of new methods are both long overdue. Encouraging signs were seen in Europe towards […]